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ABSTRACT 
Today 2.1billion people nearly 30% of world population are either obese 
or overweight. The rise in global obesity rates over the last 3 decades has 
been wide spread presenting a major public health epidemic both for the 
developed and developing world. In Ayurveda obesity is referred as 
Sthaulya. Excessive truncal adiposity is very well correlated with risk for 
diabetes, hypertension and cardiovascular disease obese people are 20% 
more likely to develop pancreatic cancer, number of GI disorder and 
hepatobiliary disorder. Mostly obesity is primary i.e., no obvious cause 
exists other than imbalance in energy intake and energy expenditure. 
Importantly modest losses of 5% to 10% of body weight have been 
shown to reduce health risk such as hyperlipidemia, hypertension and 
insulin resistance. In this research drugs are selected from Ayurvedic 
classics and the effect of Lekhaniya mahakashay is compared in Sarwang 
swedan as well as in oral medication. Overall goals of this weight loss 
management are, to prevent further weight gain, to lose weight to 
achieve a realistic target BMI and to maintain a lower body weight over 
the long term. 
 
INTRODUCTION 
Ayurveda is the oldest science ever since 
serving the world. In Modern era with continuous 
changing life styles and environment, changed diet 
habits, man has become the victim of many 
diseases and Sthaulya is one of them. Acharya 
Charaka has quoted Sthaulya under Ashta-nindita 
Purusha,[1] Acharya Charaka also lists this problem 
under Santarpanajanita Vyadhi.[2] Dalhana seems to 
be more explicit while commenting on Medo Roga 
and specified Dhatvagnimandya[3] in pathogenesis 
of the disease. An individual whose increased Meda 
and Mamsa Dhatu make his hips, abdomen and 
breasts pendulous and whose vitality is much less 
than his body size is Sthaulya. In contemporary 
medical science it is compared with obesity and it is 
defined as an excess of adipose tissue that imparts 
health risk, body weight of 20% excess over ideal 
weight for age, sex and height is considered as 
health risk.[4] It is defined by body mass index and 
further evaluated in terms of fat distribution via the 
waist hip ratio. It is most commonly caused by a 
combination of excessive food intake, lack of 
physical activity and genetic susceptibility. A few 
cases are caused primarily by genes, endocrine 
disorders, medication or mental illness and 
insufficient sleep. Obesity in India has reached 
epidemic proportion in the 21st century with mortal 
obesity affecting 5% of country population. In 
Samprapti of Sthaulya, due to Meda-Dhatwagni 
Mandya, there is excessive accumulation of Meda 
that leads to obstruction of Medovaha Strotasa. Due 
to this, there is Vimargagamana of Dosha Vata. The 
Vimarga Vayu in Koshta ultimately increases the 
Jatharagni leading to an increase in appetite. But 
because of the obstruction created by Medovaha 
Strotasa, all other Dhatus remain malnourished and 
only Meda Dhatu increases. 
  So here we made an endeavour to evolve a 
safe and complete solution for this problem with 
the help of Ayurvedic medicine and Swedan karma 
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therapy. For this research entitled “A clinical study 
to compare the effect of Lekhaniya mahakashay 
through oral administration and Sarwang swedan in 
cases of Sthaulya w.s.r. obesity” medicine are 
selected from Ayurvedic classics. 
1. Lekhaniya mahakashay kwath (Ch.su.4/3) 
2. Dashang gugglu (Bha.Pr.Chi. 8/30)  
  Dashang gugglu helps to balance Vata and 
Kapha disorder. It helps to promote healthy weight 
loss combats obesity and Ama formation and 
improves basic metabolic rate so it is considered to 
have a better result in overcoming obesity or 
Sthaulya. According to Sharangdhara any drug 
possessing Laghu and Tikshna properties Katu 
vipaka and Ushna virya performs Lekhan karma that 
is curative and absorptive action on Dosh, Dhatu, 
and Mala along with Lekhan karma. Owing to above 
said attributes these drugs improve strength of Agni 
particularly Jathragni and Dhaatwagni which 
further reduces and ultimately stops production of 
dust Medo dhatu in body. Lekhaniya mahakashay 
possess above mentioned character so its oral use is 
considered in decoction form. 
Sthaulya is a Santarpanoth vyadhi and 
Aptarpan therapy is prescribed. In Sthaulya 
Aptarpan itself contains Langhan, Rukshan and 
Swedan upkrama. So Sarvanga swedan is a better 
option for treatment of Sthaulya under concept of 
Aptarpana. 
In this research the effect of Lekhaniya 
mahakashay is compared in Sarwang swedan as 
well as in oral medication because it may be very 
convenient to patient to use it as oral medication 
rather than Sarwang swedan. 
Total 64 patients of Sthaulya were 
registered in a specialized research proforma along 
with informed consent from OPD and IPD of state 
Ayurvedic College and Hospital Lucknow, all the 
selected patients were divided into two Groups. 
Among these 5 patients were drop out. 
Group A - Patient were treated with Dashang gugglu 
2 Vati (500mg each) T.D.S + Lekhaniya mahakashay 
decoction 40ml (BD) orally. 
Group B - Patient were treated with Dashang gugglu 
2 Vati (500mg each) T.D.S+Sarwang swedan by 
Lekhaniya mahakashay kwath.  
Patients were interrogated, examined and 
investigated thoroughly by following the exclusion 
and inclusion criteria. Treatment period was of 
three months. The response of the treatment was 
recorded by periodical check up. At the end of the 
treatment Group A shows more significant result 
than treatment of Group B.  
MATERIAL AND METHODS 
Sample Size: Total 64 patients of Sthaulya were 
registered for the present study from OPD and IPD 
of R.A.C.H LKO. Among these 5 patients were drop 
out.  
Grouping: The enrolled patients of Sthaulya for the 
present clinical study were kept into two groups i.e. 
Group A with 31 patients and Group B with 28 
patients. 
Sample design 
Group A- Dashang gugglu 2 Vati (500mg each) T.D.S 
+Lekhaniya mahakashay decoction 40ml (BD) after 
meal. 
Group B- Dashang gugglu 2 vati (500mg each) T.D.S 
+Sarvang sweda with Lekhaniya mahakashay for 
two weeks daily with one week gap. 
Period of Study Trial period was of 3 months, an 
assessment of clinical feature and lab investigation 
was done after.  
Swedana Method: Samyaka Taila abhyanga was 
followed by Sarwangavaspaswedana in the 
Vashpaswedanayantra till the Samayakaswinna 
lakshan i.e., Swed-pradurbhava, Gaurava-nigraha 
and Mardava appeared. After 10-15 minutes of 
Swedana karma patients were advised to take rest 
at least for one hour. 
A. Inclusion Criteria 
1. BMI is between 30 and 45 
2. W.H.R. i.e. > 1.0 in men and > 0.85 in women.  
3. Patients between the age group of 16-60 years of 
either sex.  
4. Patient having more than 50% of the following 
major clinical symptoms was included in the trial 
(Ch.Su. 21/4). 
i) Chala Sphik Udara Stana (pendulous buttocks, 
belly and breasts) 
ii) Javoparodha (sluggishness in movement)  
iii) Krichvyavayta (difficulty in intercourse)  
iv) Swedabadha (excessive sweating) 
v) Kshudatimatrama (excessive appetite)  
vi) Daurbalyam (weakness)  
vii) Pipasatiyogam (excessive thirst)  
viii) Daurgandhyam (Foul smell) 
B-Exclusion Criteria  
Following cases were not included for the research 
study: 
a) Patients < 16 years and >60 years.  
b) Patients having BMI > 45. 
c) Patients having obesity due to secondary 
reasons such as drug induced or hormonal 
imbalance.  
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d) Patients with hypothyroidism and Diabetes 
mellitus. 
e) Patients having uncontrolled HTN (SBP> 
110mmhg), CHD, IHD and highly obese and 
evidence of Renal, Hepatic involvement. 
f) Patients having history of hereditary obesity. 
g) Patients not willing for consent. 
Criteria of Assessment 
1. Subjective Parameters 
i) Chala Sphik Udara Stana (Pendulous buttocks, 
belly and breasts) 
0 (Nil): Absence of movement. 
1 (Mild): Little movement after fast activity.  
2 (Moderate): Movement after mild activity. 
3 (Severe): No movement 
ii) Javoparodha (Sluggishness in movement) 
0 (Nil): Unimpaired movements  
1 (Mild): On desire can work sluggishly but 
properly 
2 (Moderate): on desire can work sluggishly but 
improperly 
3 (Severe): on desire cannot work 
iii) Krichvyavayta (Difficulty in intercourse) 
0 (Nil): Normal sexual performance without 
exertion. 
1 (Mild): Sexual performance with exertion. 
2 (Moderate): Sexual performance with exertion 
and breathlessness.  
3 (Severe): Sexual performance occasionally or 
monthly with exertion and breathlessness. 
iv) Daurbalyam (weakness) 
0 (Nil): No tiredness 
1 (Mild): Mild fatigue after doing work 
2 (Moderate): Tired after doing work 
3 (Severe): Works with great difficulty 
v) Daurgandhyam (Bad body odour) 
0 (Nil): Absence of odour 
1 (Mild): Occasional bad odour 
2 (Moderate): Persistent bad odour 
3 (Severe): Persistent bad odour intolerable to 
patient 
vi) Swedabadha (excessive sweating)  
0 (Nil) : Normal perspiration 
1 (Mild): Mild perspiration after doing exertion 
2 (Moderate): Heavy perspiration after doing little 
exertion 
3 (Severe): Perspiration without exertion 
Vii) Kshudatimatrama (excessive hunger) 
0 (Nil): Normal appetite 
1 (Mild): Intake of food in excess amount 
2 (Moderate): Feels hungry even after taking meal 
3 times a day.  
3 (Severe): Feels hungry even after taking meals 4 
times a day. 
viii) Pipasatiyogam (excessive thirst)  
0 (Nil): Normal intake (about 2.5 lt/day of fluid 
1 (Mild): 2.5 - 3.5 lt/day of fluid 
2 (Moderate): 3.5 - 4.5 lt/day of fluid 
3 (Severe) :> 5 lt/day of fluid 
2. Objective Parameters 
For objective parameters following examinations 
were done: 
a) B.M.I. (Body Mass Index) 
0 (Nil): B.M.I is less than 30 
1 (Mild): B.M.I is in between 30-35 
2 (Moderate): B.M.I is in between 35-40 
3 (Severe): B.M.I is between 40-45 or > 45 
b) Body weight: According to height. 
c) W.H.R. (Waist Hip Ratio)- WHR i.e., > 1.0 in men 
and > 0.85 in women indicates abdominal fat 
accumulation.  
Laboratory Investigations 
i) Routine Blood Investigation 
 -CBC- GBP - Hb% 
 -TLC 
 -DLC 
 -ESR 
ii) Urine - a) Routine (R) b) Microscopic (M) 
iii) Stool - for ova and cyst 
iv) Blood Sugar - a) Fasting b) PP 
v) Lipid profile 
 Sr. Total Cholesterol 
 Sr. Triglycerides 
 Sr. LDL 
 Sr. VLDL 
 Sr. HDL 
vi) Thyroid Function Test:  For exclusion 
vii) Liver function test: For exclusion and side 
effects 
viii) Renal function test: For exclusion and side 
effects 
Assessment of Result 
The result is assessed on the basis of 
symptoms relief and improvement in terms of 
laboratory investigations. The result of present 
clinical trial is grouped in following categories: 
1) Relieved 
i) Patients having >75% relief in terms of clinical 
symptom. 
ii) B.M.I. is less than 25. 
iii) Markedly change in Waist - hip ratio. 
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2) Improved 
i) Patients having improvement between 45-75% in 
clinical symptoms.  
ii) B.M.I. is in between 25 to 30. 
iii) Slight changes in Waist-hip ratio. 
3) No Improvement 
i) Patients having improvement less than 40% in 
clinical symptoms. 
ii) No change in B.M.I. 
iii) No change in waist-hip ratio. 
Observation and Result 
Table 1: Comparison of change in Chala Sphik, Udara, Stana before to after treatment 
Groups Before treatment After treatment Mean change z-value p-value1 
Group A 2.35±0.75 1.16±0.93 1.19±.70 4.41 0.0001* 
Group B 2.29±0.66 1.71±0.98 .58±.50 2.13 0.0001* 
Z-value .54 -1.98    
p-value2 .58 0.04*    
1Wilcoxon rank sum test, 2Mann-Whitney U test, *Significant
Table 2: Comparison of change in Javoparodha before to after treatment 
Groups Before treatment After treatment Mean change z-value p-value1 
Group A 2.39±0.76 0.32±0.48 2.07±.62 6.32 0.0001* 
Group B 2.36±0.78 0.64±0.78 1.72±.65 5.33 0.0001* 
Z-value .12 -1.30    
p-value2 .90 0.19    
1Wilcoxon rank sum test, 2Mann-Whitney U test, *Significant 
Table 3: Comparison of change in Krichhavyavayata before to after treatment
Groups Before treatment After treatment Mean change z-value p-value1 
Group A 1.90±01.08 .13±0.34  1.77±.99 5.25 0.0001* 
Group B 1.79±01.07 0.68±0.77  1.10±.78 3.62 0.0001* 
Z-value 0.46 -2.58    
p-value2 0.645 0.009    
1Wilcoxon rank sum test, 2Mann-Whitney U test, *Significant
Table No. 4: Comparison of change in Swedabadha before to after treatment 
Groups Before treatment After treatment Mean change z-value p-value1 
Group A 1.81±1.01 .23±0.50 1.58±.15 5.29 0.0001* 
Group B 2.11±0.69 .43±0.79 1.68±.54 5.34 0.0001* 
Z-value -0.94 -0.68    
p-value2 0.342 0.496    
1Wilcoxon rank sum test, 2Mann-Whitney U test, 
Table 5: Comparison of change in Kshudatimatrama before to after treatment
Groups Before treatment After treatment Mean change z-value p-value1 
Group A 1.26±1.03 .19±0.40 1.07±.14 4.03351 0.0001* 
Group B 1.68±1.02 .36±0.49 1.32±.77 4.44903 0.0001* 
Z-value -1.51 -1.07    
p-value2 0.13 0.28    
1Wilcoxon rank sum test, 2Mann-Whitney U test, *Significant 
Table 6: Comparison of change in Daurbalyam before to after treatment 
Groups Before treatment After treatment Mean change z-value p-value1 
Group A 2.19±0.83 0.68±0.83 1.51±.72 5.11 0.0001* 
Group B 2.07±0.90 0.75±0.65 1.32±.61 4.67 0.0001* 
Z-value 0.47 -.67    
p-value2 0.63 0.49    
1Wilcoxon rank sum test, 2Mann-Whitney U test, *Significant 
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Table 7: Comparison of change in Pipasatiyogam before to after treatment 
Groups Before treatment After treatment Mean change z-value p-value1 
Group A 1.94±0.93 0.32±0.75 1.62±.16 5.20 0.0001* 
Group B 2.18±0.98 0.64±0.73  1.53±.79 4.76 0.0001* 
Z-value 0.39 -2.79    
p-value2 0.25 0.06    
Table 8: Comparison of change in Daurgandhyam before to after treatment 
Groups Before treatment After treatment Mean change z-value p-value1 
Group A 2.03±0.87 0.35±0.66 1.68±.70 5.52 0.0001* 
Group B 1.89±0.99 1.11±1.03 .78±.68 2.63 0.0001* 
Z-value 0.39 -2.79    
p-value2 0.69 0.001    
1Wilcoxon rank sum test, 2Mann-Whitney U test 
Table 9: Comparison of change in Weight before to after treatment 
Groups Before treatment After treatment Mean change z-value p-value1 
Group A 84±11.74 76.13±10.61 7.87±2.34 3.01 0.0001* 
Group B 83.64±14.42 79.25±14.59  4.39±1.28 1.54 0.0001* 
Z-value .54 -.59    
p-value2 0.91 0.34    
1Wilcoxon rank sum test, 2unpaired t test, *Significant 
Table 10: Comparison of change in BMI before to after treatment 
Groups Before treatment After treatment Mean change z-value p-value1 
Group A 33.99±3.09 30.75±2.66 3.24±.17 3.90 0.0001* 
Group B 34.51±3.41 32.67±3.38 1.84±.55 2.11 0.0001* 
Z-value .54 -2.24    
p-value2 .54 0.01    
1Wilcoxon rank sum test,, 2unpaired t test, *Significant 
Table 11: Comparison of change in WHR before to after treatment 
Groups Before treatment After treatment Mean- change z-value p-value1 
Group A 0.91±.05 0.89±0.06 0.02±.009 1.71 0.0001 
Group B 0.93±0.14 0.91±0.12 0.02±.03 .57 0.0001 
Z-value -.46 -.74    
p-value2 .43 .43    
1Wilcoxon rank sum test, 2unpaired t test, * 
Table 12: Comparison of biochemical parameters from before to after treatment between the groups 
Time interval Group A Group B p-value1 
Hb (gm/dl)    
Before 11.2±1.40 11.43±1.58 0.54 
After 11.67±1.20 11.82±1.226 0.64 
Mean change, p-value2 0.62±.92, 0.0001* 0.32±.54, .0008*  
TLC ( cells/mm3)    
Before 7645.16±1746.78 7639.29±1586.83 .98 
After 6654.84±1115.3 6921.43±1108.34 .36 
Mean change, p-value2 -990.32±1158.3, 0.0001* -717.86±1080.8, .0016*  
Neutrophil (%)    
Before 61.87±7.84 61.43±7.88 0..82 
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After 61.39±7.48 60.54±7.42 0.66 
Mean change, p-value2 -0.48±.88, 0.005* -0.89±1.1, 0.0002*  
Eosinophil (%)    
Before 1.94±2.10 1.57±1.45 0.44. 
After 1.10±1.49 1.00±1.05 0.77 
Mean change, p-value2 -0.83±1.18, 0.0005* -0.57±.92, 0.002*  
Basophil (%)    
Before 0.35±0.55 0.32±0.55 .81 
After 0.26±0.44 0.29±0.46 .81 
Mean change, p-value2 -0.09±.39, 0.18 -0.03±.33, 0.57  
Monocytes (%)    
Before 1.06±1.71 .46±.92 0.10 
After 0.74±1.32 0.75±1.27 0.98 
Mean change, p-value2 -0.32±.59, 0.005 -0.29±1.08, 0.17*  
Lymphocytes (%)    
Before 32.35±9.45 34.50±11.82 0.44 
After 31.52±8.86 33.46±11.06 0.45 
Mean change, p-value2  -.83±1.18, 0.04*  -1.04±2.0, 0.01  
ESR (mm/hr.)    
Before 19.32±6.85 22.86±7.31 0.06 
After 16.65±3.41 16.79±4.15 0.88 
Mean change, p-value2 -2.67±5.00, 0.00057* -6.07±5.4, 0.0002*  
1Unpaired t-test, 2Paired t-test, *Significant 
Table 13: Comparison of Lipid Profile from before to after treatment between the groups 
Time interval Group A Group B p-value1 
TC(mg/dl)     
Before 218.71±23.02 215.14±23.84 0.56 
After 189.88±21.88 195.71±18.59 0.17 
Mean change, p-value2 28.48±15.4, 0.0001* 19.43±12.4, 0.0001*  
TG(mg/dl)     
Before 171.68±44.82 166.21±41.02 0.62 
After 146.68±37.4 151.64±36.57 0.60 
Mean change, p-value2 25.00±28.7, 0.0001* 14.57±12.7, 0.0001*  
HDL(mg/dl)     
Before 42.00±10.11 40.29±5.83 .43 
After 44.14±10.90 41.71±10.90 .28 
Mean change, p-value2 1.41±5.25, 0.0003* 2.14±2.75, 0.1424*   
LDL(mg/dl)     
Before 128.06±18.72 125.36±11.68 0.51 
After 115.65±16.78 115.86±11.08 0.42 
Mean change, p-value2 12.49, ±6.70.0001* 12.7±6.3, 0.0001*  
VLDL(mg/dl)     
Before 46.23±10.72 33.18±8.09 0.0001* 
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After 39.06±9.27 29.91±7.07 0.0001* 
Mean change, p-value2 7.17±4.7, 0.0001* 3.17±2.32, 0.0001*  
1Unpaired t-test, 2Paired t-test, *Significant 
Table 14: Comparison of Blood Sugar level from before to after treatment between the groups
Time interval Group A Group B p-value1 
Fasting(mg/dl)     
Before 82.43±10.10 83.57±9.74 0.66 
After 81.12±9.92 82.21.±9.80 0.67 
Mean change, p-value2 1.31±2.8, 0.0149* 1.35±0.82, 0.0001*  
PP(mg/dl)     
Before 134.16±13.58 142±15.27 0.04 
After 130.68±12.85 139.39±15.24 0.02* 
Mean change, p-value2 3.48±2.9, 0.0001* 2.61±2.5, 0.0001*  
1Unpaired t-test, 2Paired t-test, *Significant 
Table 15: Overall improvement in the severity of symptoms
 Group A Group B 
 No. % No. % 
Relieved 21 67.74 10 35.72 
Improved 10 32.26 15 53.57 
Not improved 0 0 3 10.71 
Overall Effect of the Trial Drugs 
There was significant relief in both the 
treatment of group A and group B, but treatment of 
group A is more significant than group B. 
DISCUSSION 
Acharya Charaka has mentioned Sthaulya as 
a Santarpan janya vyadhi, Charak Samhita has also 
considered Sthaulya one among the Astanindita 
vyadhi. Sushruta Samhita has considered it as Rasa 
Nimittaja Vyadhi. Madhavakara has described 
Medoroga as individual entity in 34th chapter of 
Madhava nidana and used Medosvina, Atisthula and 
Sthula words as synonym.  
Nidana of Sthaulya 
Nidana of Sthaulya is divided in four 
categories Aharatmaka, Viharatmaka, Manasa and 
Anya. The modern lifestyle in terms of fast foods, 
increased luxury, lack of physical work, have 
contributed to the etiology of Sthaulya. Achintanach 
and Harsanityatva are the Mansika causes but now 
a day’s stress is also a causative factor because its 
leads to the vigorous demand for the food which 
leads to the Sthaulya. 
Samprapti 
Samprapti of Sthaulya can be divided in to 
two categories.  
1) Samprapti, according to Charaka samhita is Due 
to obstruction of Srotas by Meda, the Vata 
moving mainly into stomach, whips up the Agni 
(Tikshnagni) and absorbs the food. The diseased 
man digests food speedily. Excessive eating 
produces more production of Rasa which causes 
over growth of Meda Dhatu leading to Sthaulya, 
increased Jatharagni, which leads to excessive 
formation of improper Medodhatu leading to 
Sthaulya. 
2) According to Acharya Sushruta Ama Rasa is 
produced due to Kaphavardhaka Ahara, 
Adhyashana, Avyayama, Divaswapa. The Madhura 
Bhava Ama Rasa moves with in the body, 
Snigdhamsha of this Anna Rasa causes Sthaulya, 
which produces excessive Medodhatu and this is 
according to Dalhana in which there is a state of 
Medodhatvagni mandya which leads to excessive 
formation of improper Medodhatu leading to 
Sthaulya.  
The hypothesis decided for the study was if we 
treat the Santarpan janya vyadhi by Apatarpana 
dravyas, Vyadhi will automatically get treated. To 
prove this hypothesis a conceptual and clinical 
study was performed in the patients of Sthaulya. 
Roopa: Rupas of Sthaulya are compiled from 
various classics. Out of them, 8 most common 
symptoms of Sthaulya occur due to excessive 
accumulation of Meda in fat depots leading to 
Chalatva of the various organs, Daurabalya, 
Dauragandhya, Kshudhaadhikya, Pipasatiyoga, 
Swedaadhikyata, Nidraadhikya, Kshudra shwasa, 
Angagauravata Su.su.15/37 other various signs and 
symptoms. Regarding the differential diagnosis of 
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the disease, Sthaulya can be easily spotted by just 
Darshana Pariksha. 
Mode of Action of Drug as Per Modern View-
constituent of Lekhaniya mahakashay has choleretic 
and purgative action since bile salt are required for 
absorption of fat and lipid from gut, their excretion 
would lead to decreased absorption of fat and lipids 
in gut increasing faecal fat and bile salt content 
leading to decrease in obesity. 
Mode of Action of Dashang Gugglu 
Mode of Action of Lekhaniya Mahakashay 
Discussion on Clinical Symptoms  
Chala Sphik Udara Stana 
Considerable relief in the symptoms of 
Chala sphika–udara- stana was observed in patients 
of Group A (Z=4.41, p<0.0001) and in patient of 
group B (Z=2.213, p<0.0001). This might be due to 
Sphik-Udara –Stana are the main site of excess Medo 
deposition and maximum contents of Dashang 
gugglu and Lekhaniya mahakashay have Medohara 
properties which lead to reduction of excess Medo 
Dhatu from these sites. 
 
Javoparodha 
Considerable relief in the symptoms of 
Javoparodha was observed in patients of Group A 
(Z=6.32, p<0.0001) and in patient of group B 
(Z=5.33, p<0.0001). The Shaithilya (flabbiness), 
Saukumarya (delicacy) and Guruta properties of 
Meda Dhatu causes Javoparodh along with raised 
Alasya because of vitiated Kapha. Thus these 
persons are slow to initiate the work.  
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Due to Ama Pachana, Kapha Nashaka and Medohara 
effect of trial drugs helped in minimizing this 
symptom. 
Krichvyavayta 
Considerable relief in the symptoms of 
Krichhavyavayata was observed in patients of 
Group A (Z=5.25, p<0.0001) and in patient of group 
B (Z=3.62, p<0.0001). The trail drugs have Dipana, 
Pachana, Medohara and Strotoshodhak property 
which causes Ama Pachana by virtue of which Uttar 
Dhatu got nourishment and reduced Medodhatu 
over the Sphika, Udara, Stana also helps to reduce 
the Krichhavyavayata. However, modern 
researchers have studied the relation between 
weight loss and improvement in sexual functions 
also.[5] 
Swedabadha 
Considerable relief in the symptoms of 
Swedabadha was observed in patients of Group A 
(Z=4.03, p<0.0001) and in patient of group B 
(Z=4.44, p<0.0001). This is due to the fact that 
Sweda (sweat) is a Mala (metabolic by product) of 
Medodhatu. During normal metabolism of this 
tissue sweat is produced but in normal quantities to 
maintain the normal physiological phenomenon. 
However, in Obesity, the metabolism of Medas is 
greatly hampered due to a Medodhatvagnimandya. 
As a result, the Dhaturupa medas is formed less and 
Malarupa Sweda is formed in excess. With the trial 
regimen, as already seen, this Dhatvagnimandya is 
corrected and the normal metabolism process is re 
established so that the Medodhatu is formed 
qualitatively and there occurs a decrease in the 
Malarupa Sweda.  
More over Obesity is a condition associated 
with physiological increase in the sympathetic arm 
of the autonomic nervous system.[6] The excessive 
sweating observed in the subjects may be attributed 
to this increased sympathetic activity. Further, It is 
also demonstrated that parasympathetic activity 
increased with weight loss in obese.[7] Thus, the 
decrease in the symptom excessive sweating may 
be explained in terms of reestablishment of 
sympathetic-parasympathetic balance due to 
weight loss. 
Kshudatimatrama 
Considerable relief in the symptoms of 
Kshudatimatrama was observed in patients of 
Group A (Z=4.03, p<0.0001) and in patient of group 
B (Z=4.44, p<0.0001). 
The status of Agni in Atisthaulya needs a 
precise understanding. The indulgence in Kapha 
vitiating etiological factors initially results in a 
Jaṭharagnimandya. This in turn leads to the 
formation of Amasamyukta annarasa (improperly 
digested Annarasa). This poorly formed Annarasa 
initiates Dhatvagnimandya at the level of Rasa 
dhatu. Subsequently, Ama accumulation takes place 
at the Dhatu level and the Rasadhatu formed is 
qualitatively not sufficient to perform its function of 
Prinana (nourishment of other tissues). This 
Amasamyuktarasadhatu sequentially diminishes the 
strength of succeeding Dhatvagnis and as a result, 
there occurs a morbid Amasancaya resulting in 
Srotorodha at the Kostha with a resultant Vatakopa. 
This, secondarily, causes a pathological flaring up of 
the Jaṭharagni.[8] Due to maximum content of trial 
drug have Dipana Pachana Properties with Kashaya, 
Katu and Tikta Rasa. These are Kapha Shamaka and 
Ama Pachaka, as a result Jatharagni and Dhatvagni 
are normalized. 
Daurbalyam 
Considerable relief in the symptoms of 
Daurbalyam was observed in patients of Group A 
(Z=5.11, p<0.0001) and in patient of group B 
(Z=4.67, p<0.0001). Due to Srotorodha of different 
(Rasa and Meda) Srotas by Ama, nourishment of 
rest of Dhatu are diminished, thus it will not 
transport nutrient to Uttar Dhatu. Hence, it causes 
Dhatu Kshaya which results in to Ojakshaya which 
may lead to Daurbalya.  
The trial drugs have Dipana, Pachana, 
Medohara and Strotoshodhak property which 
causes Ama Pachana by virtue of which Uttar Dhatu 
got nourishment.  
Pipasatiyogam 
Considerable relief in the symptoms of 
Pipasatiyogam was observed in patients of Group A 
(Z=5.11, p<0.0001) and in patient of group B 
(Z=4.67, p<0.0001). In patients of obesity 
Pipasadhikya is because of Pitta dosha and Prakupit 
vata dosha, the trial drugs have Tikta, Kashaya rasa 
and Ama Pachana properties by that Medodhatu 
reduced and the Avarana break down which lead to 
normalize Pitta and Vata so the symptom may got 
reduced. 
Daurgandhyam 
Considerable relief in the symptoms of 
Daurgandhyam was observed in patients of Group A 
(Z=5.52, p<0.0001) and in patient of group B 
(Z=2.63, p<0.0001). Sweda is stated as Mala of 
Meda.[9] Due to excessive Vikriti medodhatu, Gatra 
dauragandhya present in obese patients. Trial drugs 
have property of Strotoshodana leads to the 
formation of normal Medodhatu and decrease the 
above symptoms.  
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Discussion on Objective Parameters 
Body Weight 
There was highly significant (p=0.0001) 
mean change in the weight from before to after 
treatment in both group. The mean change in 
weight between the groups was not found to be 
significant (p>0.05). The decrease was found to be 
higher in Group A (p=.002, z= 3.01) than Group B 
(p= .12, z=1.54). The decrease in the body weight 
attributed to the choleraetic and purgative action[10] 
of constituent of Lekhaniya mhakashay. Since bile 
salt are required for absorption of fat and lipids in 
gut their excretion would lead to decreased 
absorption of fat and lipids in gut increasing faecal 
fat and bile salt content leading to decrease in 
weight.  
Body Mass Index (BMI) 
There was significant mean change in the 
BMI from before to after treatment in both the 
groups. The mean change in BMI between the 
groups was also found to be significant (p=0.01). 
The decrease was found to be higher in Group A 
(mean change=3.24±.17) than Group B (mean 
change=1.84±.55). 
Due to reduction of weight and Medo dhatu BMI is 
also reduced. 
Waist hip ratio 
There was insignificant (p>0.05) mean 
change in the WHR from before to after treatment 
in both the groups. The difference in the mean 
change in WHR between the groups was found to be 
insignificant (p>0.05). The decrease was found to 
be slightly higher in group A (z=1.71) than group B 
(z=.57). waist (Udara) and hip (Sphik) are also the 
main site of deposition of Meda, so reduction in 
Meda may causes the reduction in waist and hip 
ratio. 
Discussion on Laboratory Parameters 
Hemoglobin 
There was an increase in the Haemoglobin 
concentration at the end of the intervention, 
however the change was significant (P<0.001) in 
both the groups. Under normal physiology, the 
Rasadhatu is transformed into the Raktadhatu. In 
Atisthaulya with a malfunctioning of Dhatvagni, 
specifically Raktadhatvagni here, this 
transformation is impaired evident by the 
decreased Haemoglobin concentration before the 
intervention. After the intervention, due to 
reestablishment of the normal physiological 
functioning of the Dhatvagnis the mobilization of 
the Ahararasa to corresponding Dhatus is ensured, 
thereby yielding a qualitative and quantitative 
improvement in Raktadhatu as observed with the 
increase in Hemoglobin concentration.  
Renal Function Tests 
All the Renal Function Tests were observed 
to be within physiological normal limits on Day 0. 
At the end of intervention, significant change was 
seen in the values.  
B. Urea 
There was significant (p=0.0001) decrease 
in both the groups from pre to post treatment. Thus, 
the safety of the trial drugs with respect to renal 
functioning can be assured.  
Liver Function Test 
In the present study the liver functions were 
found to be within physiological normal limits on 
Day 0. This indicates that the obesity in the study 
subjects was not an outcome of a pathological 
metabolic error, rather was a consequential of an 
energy imbalance.  
A significant (p<0.05) decrease was 
observed from pre to post treatment in alkaline 
phosphate, SGOT and SGPT. However, all the 
changes were within the normal physiological limits 
confirming the hepato-protective action of the trial 
drug. 
Lipid Profile  
S. Cholesterol in patients of both the Group A and B 
the decrease was statistically highly significant 
(p=0.0001). 
S. Triglyceride in patients of both the Group A and 
B the decrease was statistically highly significant 
(p=0.0001). 
S. HDL in patients of Group A, the increase was 
statistically highly significant (p<0.001). The change 
was not significant in between the Groups. HDL is 
considered as good cholesterol because of its 
effectiveness in cholesterol removal from periphery 
to liver (reverse cholesterol transport). 
S.LDL in patients of both the Group A and B the 
decrease was statistically highly significant 
(p=0.0001). 
VLDL in patients of both the Group A and B the 
decrease was statistically highly significant 
(p=0.0001). 
Meda, Majja, Vasa which are Sneha Dravya can be 
correlated with lipids since they have properties 
and function similar to that of lipids. The trial drugs 
have Ruksha Guna and Laghu Guna like properties 
which are known for its Dhatu Shoshaka, Rukshana 
and Lekhana Karma. Due to their Rukshana Lekhana 
properties they results in reduction of lipids from 
body which might help in minimizing these 
biochemical matters. 
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Discussion on Final Result 
In Group A, 21 patients (67.74%) were 
relieved and 10 patients (32.26%) were improved 
by administration of the trial drugs. 
In Group B, 10 patients (35.72%) were 
relieved, 15 patients (53.57%) were improved and 
3 patients (10.71%) were not improved by the 
administration of the trial drugs. The comparison 
between Group A and B reveals that the percentage 
of relieved patients is higher in Group B than in 
Group A. This difference is statistically significant as 
(p=0.01). 
CONCLUSION 
 Sthaulya is a Dushya dominant Vyadhi. 
 Medo is the main Dushya and Kapha is the main 
Dosha of Sthaulya. 
 Acharya Charaka considered Atisthaulya Purusha 
as one out of the Asthanindtiya Purusha.  
 Excessive indulgence in oily and fatty food, 
sedentary life style, Divaswapna, Manasika 
factors like-Harshanitya, Manasonivrita etc., 
along with genetic predisposition play a major 
role in aetiopathogenesis of Sthaulya. 
 Acharya Charaka has specially mentioned 
Beejadosha as the Nidana for Sthaulya. 
 Sushruta Samhita has considered Rasa as the 
major pathological factor involved in obesity.  
 The etiological factors lead to Kapha and Meda 
vraddhi which block the micro channels causing 
Samana vayu vitiation in the Koshtha and causes 
Jatharagni Sandhukshana thereby increasing the 
person’s appetite and increased intake of food 
ultimately leading to Sthaulya Roga (Medodhatu 
vriddhi). 
 Due to obstruction by Meda, Vyana vayu could 
not transport nutrient to other Dhatu so 
Medadhatu is increased and Uttara dhatu are 
decreased. 
 Restoration of Agni to normal physiological 
states, removal of Medaavarana and 
accumulated Sama meda from the body are the 
main principle of treatment of this disease.  
 On basis of the Etiopathogenesis and literary 
meaning Sthaulya can be correlated with Obesity. 
 Obesity is widespread in almost all socio-
economic classes. 
 Majority of the patients i.e., 12 (35.29%) of group 
A and 9 (30%) of group B belong to third and 
fourth decade of life. 
 Females were more prone to obesity i.e., 27 
(79.41%) in group A and 24 (80%) in group B 
were females.  
 Maximum number of the patients i.e., 29 (85.3%) 
in group A and 26 (86.67%) of group B were 
married. 
 Sthaulya is more common in people addicted to 
tea (61.76% in group A and 56.67% in group B) 
and taking mixed food (64.70% in group A and 
70%in group B).  
 Vishamasan (55.8% in group A and 50% of group 
B) is observed as main dietary habit in patients 
of obesity. 
 In females, menstrual disorder is more common 
among associated disease i.e., 29.41% (10) of 
group A and 26.67% (8) of group B were having 
menstrual disorder. 
 Acharya Charaka explanation of Sthaulya 
matches with phenotype of density. W.H.R and 
skin fold thickness can be taken as parameter to 
assess the Sthaulya, as W.H.R helps to check the 
abdominal fat (Chala udara)and gluteal fat 
(Chala sphika) and skin fold thickness helps to 
measure regional fat (Chala stana). 
 The trial drug Lekhaniya Mahakashay is effective 
in the disease due to their Deepana, Pachana, 
Lekhana, Rukshana, Medohara, Srotoshodhana, 
Aamapachana, Vatanulomana, Kaphaghna etc. 
properties. 
 As Sthaulya it is a Santarpanoth vyadhi and also 
Kashtasadhya so Apatarpana chikista like Swedan 
is prescribed for Sthaulya.  
 As Gugglu has Srotosodhak property and 
Medoanil haranam property so it plays a great 
role in treatment of obesity.  
 Therapeutic efficacy of Group A was significantly 
higher than Group B.  
 In Group A, 21 patients (67.74%) were relieved 
and 10 patients (32.26%) were improved by 
administration of the trial drugs. 
 In Group B, 10 patients (35.72%) were relieved, 
15 patients (53.57%) were improved and 3 
patients (10.71%) were not improved. 
 Both the group showed significant improvement 
in all subjective parameter.  
Both the group showed significant improvement 
on body weight, BMI and WHR.  
 No any biochemical abnormalities have been 
observed in registered cases after completion of 
trial it indicates safety of the trial drug. 
 Both the trial drug was found effective as lipid 
lowering agent so can be used in dyslipidemia. 
 The response of treatment in Group A is more 
than Group B, the intergroup comparison was 
statistically significant. So, the therapeutic 
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response among the patients included in this 
study was encouraging. 
 Thus it can be concluded that Lekhaniya 
Mahakashay kwath along with Dasang gugglu is 
proved to be an effective therapy and this 
regimen should be tested on large scale for long 
duration of trial. 
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